The objective of the study was to identify the mechanism of action for a radiation mitigator of the gastrointestinal (GI) acute radiation syndrome (ARS), identified in an unbiased high-throughput screen. We used mice irradiated with a lethal dose of radiation and treated with daily injections of the radiation mitigator 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine to study its effects on key pathways involved in intestinal stem cell (ISC) maintenance. RNASeq, quantitative reverse transcriptase-polymerase chain reaction, and immunohistochemistry were performed to identify pathways engaged after drug treatment. Target validation was performed with competition assays, reporter cells, and in silico docking. 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine activates Hedgehog signaling by binding to the transmembrane domain of Smoothened, thereby expanding the ISC pool, increasing the number of regenerating crypts and preventing the GI-ARS. We conclude that Smoothened is a target for radiation mitigation in the small intestine that could be explored for use in radiation accidents as well as to mitigate normal tissue toxicity during and after radiotherapy of the abdomen.
radiation-induced loss of tissue function. In the small intestines, finger-like structures called villi form a large epithelial surface responsible for the absorption of nutrients. The epithelial cells of these villi originate from intestinal stem cells (ISCs) found at the base of cryptlike structures surrounding the villi. 5 Rapidly proliferating transiently amplifying cells produce differentiated progeny that migrate toward the tip of the villi in a conveyer belt-like fashion where they shed into the intestinal lumen and die. In response to irradiation the villi are lost but depending on the radiation dose, the tissue is restored over time by the surviving ISCs able to initiate regenerating crypts. 4 In the event of an exposure to radiation during nuclear accidents, or by nuclear explosive devices and "dirty bombs," treatments are needed to mitigate radiation damage to the hematopoietic system and the gut, in order to prevent ARS. 6, 7 Mass-casualty scenarios come with multiple logistic challenges that make successful distribution of drugs to a large number of victims within the first 24 hours after an incident unlikely. [8] [9] [10] Currently, there are very few drugs known to mitigate the effects of radiation when applied 24 hours after radiation exposure or later. 7 A recent high-throughput screen performed by the UCLA Center for Medical
Countermeasures against Radiation identified compounds with radiation mitigator properties to the hematopoietic system and the gut. 11, 12 Among these compounds, 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine (compound #5; Figure 1A ) most efficiently mitigated hematopoietic and GI-ARS. However, the underlying mechanisms of action were not investigated 12 and are addressed in our present study.
Here, we hypothesized that drugs that successfully mitigate radiation damage in the small intestine impact ISC survival and/or expansion. We report that compound #5 modulates Hedgehog signaling in 
| Irradiation
Twelve-week-old C3Hf/Sed/Kam mice were irradiated in groups of five animals using an experimental x-ray irradiator (Gulmay Medical Inc, Atlanta, Georgia) at a dose rate of 2.8159 Gy/minute for the time required to apply a prescribed dose. Radiation was administered between 11:30 a.m. and 1:30 p.m. to minimize variation of circadian effects on radiation responses. 13 Control animals were sham-irradiated. The x-ray beam was operated at 300 kV and hardened using a 4 mm Be, a 3 mm Al, and a 1.5 mm Cu filter. For total abdominal irradiation (TAI) the rest of the body was shielded with 10 mm lead blocks. 
| In vivo drug administration

| Microcolony stem cell assay
Mice were irradiated with 16 Gy TBI. Twenty-four hours after irradiation, the animals were treated with compound #5, as described above, and were treated daily until tissue harvesting. 
Significance statement
Exposure to lethal doses of ionizing radiation manifests in a symptom complex that is summarized as acute radiation syndrome (ARS) and the extent of radiation damage to the hematopoietic and gastrointestinal (GI) systems codetermine the acute survival of the exposed individual. So far, no person who experienced a full-scale GI-ARS has ever survived.
This creates a-so far-mostly unmet need to develop countermeasures that mitigate the effects of lethal radiation doses when given after radiation exposure. This study presents that a piperazine compound prevents GI-ARS in mice when given 24 hours after a lethal dose of radiation and uncovers the underlying mechanism of action, thus providing a basis for a future rational development of effective radiation mitigators. 14, 15 Gene sets with corrected P-values less than .05 were considered significantly enriched by differential expressed genes.
| Quantitative reverse transcription PCR
| Immunohistochemistry
Cross-sections of the small intestines were fixed in formalin, embed- 
| Enteroid isolation
Intestinal enteroids were prepared as previously described. 16 Briefly, mice were sacrificed and the small intestine was harvested, flushed with phosphate buffered saline (PBS) and opened longitudinally. The villi were then scraped off using an ice-cold glass slide, washed with PBS (×3), chopped into small segments, dropped in a 50 mL tube containing 20 mL of ice-cold PBS with Pen/Strep and washed by pipetting up and down. After segments were allowed to settle by gravity, the supernatant was discarded and the procedure was repeated approximately 15-20 more times until the solution was clear.
The intestinal segments were resuspended in PBS with 5 mM EDTA and rocked at 20 rpm for 15 minutes at room temperature. The segments were then allowed to settle by gravity and the pellets resuspended in 10 mL of ice-cold PBS with 0.1% BSA, pipetted three times and allowed to settle. The supernatant was collected, passed through a 70 μm filter into a 50 mL tube and saved as fraction 1 (F1).
The procedure was repeated to obtain fractions 2-4 (F2-F4). The frac- 
| Quantitative budding crypt assay
Budding crypt assays were conducted by plating 60 μL of crypt mixture, containing 150 crypts (for wells treated with radiation) or 50 crypts (for nonirradiated controls), into each well of a prewarmed 96-well plate. The Matrigel was allowed to solidify and then complete IntestiCult Organoid Growth Medium was slowly added to cover the embedded crypts. The plate was incubated at 37 C overnight and irradiated the following day with 0 Gy or 3 Gy. Compound #5 was added 3 hours or 24 hours later and the media was changed daily for 6-8 days. The number of enteroids with budding crypts was determined once the crypts reached maturity.
| R-Spondin1 replacement assay
Intestinal enteroids from 6 to 8-week-old female C3H mice were prepared as described above. Enteroids were dissociated into crypts and resuspended in 1: 
| Statistics
All analyses were performed in the GraphPad Prism software package.
Two-sided Student's t tests and a two-way analysis of variance for multiple comparisons were used. A log-rank test was used to determine a P-value for the Kaplan-Meier survival curves in Figure 1 . A P-value equal to or smaller than .05 was considered statistically significant. 
| Compound #5 promotes crypt regeneration and expands the stem cell compartment
Accidental radiation exposure will rarely be restricted to the abdomen and Mason et al demonstrated that at high radiation doses ISC survival in mice is independent of the irradiation technique (TBI or TAI). 20 Therefore, to test the effect of compound #5 on the survival of ISCs, animals were treated with 16 Gy TBI (LD 50/10 ). 20 Twenty-four hours after irradiation administration of compound #5 (5 mg/kg) in DMSO/ Cremophor, or DMSO/Cremophor only was started and administered daily. Animals were euthanized 96 hours after irradiation and crosssections of the small intestines were analyzed for the appearance of regenerating intestinal crypts ( Figure 1E,F) . In animals irradiated with 16 Gy, However, compound #5 did not affect the number of Ki67-positive nuclei in unirradiated tissues ( Figure 3A ,B,E, P = .3612). In nonirradiated animals, Ki67 staining was most prominent in the region of transiently amplifying cells and-although weaker-also present in crypt base columnar cells (CBC cells; Figure 3B ).
To test the effect of compound #5 on the function of ISCs more directly, we generated intestinal enteroids from the small intestines of C3H mice and treated the enteroid cultures with a single dose of 3 Gy in vitro, followed by addition of compound #5 either 3 hours or 24 hours postirradiation. The number of enteroids with budding crypts was determined after 6 days. A significant increase in the number of functional enteroids (able to generate crypt structures, Figure 3F , white arrows) was observed when compound #5 was added 3 hours after irradiating the intestinal enteroids in vitro (P = .0479, Figure 3G ). significantly increased the number of budding enteroids. This indicated that compound #5 has a different molecular target than R-Spondin1, which sustains and amplifies Wnt signaling.
| Compound #5 induces an acute immunological response in the small intestines
At this point in our study the molecular target for compound #5 was unknown, which hindered further optimization of the drug. Therefore, . Surprisingly, RNASeq resulted in the differential expression of only 15 genes in animals treated with compound #5 (Figure 4A,B) .
The upregulation of six of these genes was confirmed using qRT-PCR ( Figure 4C ) Gene set enrichment analysis computed overlaps with immunological signatures (Figure 4D ), which was in agreement with our previous report of increased cellularity in Peyer's patches, the immune system of the gut, after treatment with compound #5. 21 
| Effects of compound #5 on developmental signaling pathways in the intestinal crypt
Since the increased number of regenerating crypts after treatment with compound #5 pointed to increased numbers of ISCs we next studied if pathways known to be involved in ISC renewal were activated in response to compound #5 treatment. Because ISCs are particularly dependent upon Wnt pathway activation and the Wnt . E, Female, 12-week-old C3H mice were subjected to 16 Gy total body irradiation. Twenty-four hours later, the mice were treated with Cremophor/DMSO or compound #5 (5 mg/kg) subcutaneously. Twenty-four hours after compound #5 treatment (48 hours after irradiation), intestines were removed, fixed, and thin cross-sections were stained for Notch1-ICD, the active form of Notch1. Compound #5 did not increase Notch1-ICD staining in vivo, thus excluding Notch1 as a target for compound #5. Scale bar: 100 μM. F, Small intestines of C3H mice were removed and crypts were isolated and cultured for propagating intestinal enteroids in vitro. Enteroids were treated with DMSO or compound #5 (10 μM) for 24 hours. The enteroids were removed from the matrix and attached to slides using a cytospin (Shandon Elliot, Tacoma, Washington). The slides were fixed, permeabilized, and stained for YAP/TAZ and a nuclear counterstain. The slides were imaged using confocal microscopy. Compound #5 not affect the nuclear localization of YAP/TAZ, suggesting that the Hippo signaling pathway was not affected by compound #5. Scale bar: 50 μM pathway drives many of the canonical stem cell markers of the small intestine, we assessed whether compound #5 activated Wnt signaling in vivo. Staining against β-catenin at 48 hours after irradiation and 24 hours after drug treatment revealed weak stabilization and nuclear translocation of β-catenin ( Figure 5A -D) thus, indicating that compound #5 does not significantly activate the Wnt signaling pathway directly or indirectly. Furthermore, this analysis was hindered by the variation of β-catenin staining in each circumference and the known gradual 10-fold decrease of Wnt signaling from the proximal to the distal small intestines. 22 Next, we tested if compound #5 activated Notch signaling, a second pathway that is involved in the maintenance of the intestinal crypt. 23 Staining compound #5-treated section with an antibody against Notch1-ICD, the intracellular domain of the cleaved, active form of Notch1 showed variation of Notch activation in the individual circumferences but no clear Notch activation pattern in response to compound #5 ( Figure 5E ).
The Hippo pathway is also critical during crypt regeneration after injury, including radiation injury. 24 Hippo pathway components YAP/TAZ are activated and localized to the nucleus during recovery from radiation injury. We assayed for Hippo pathway activation using in vitro enteroids treated for 24 hours with compound #5 or DMSO.
The enteroids were fixed, stained with antibodies against YAP/TAZ and a nuclear counterstain (DAPI) and analyzed by confocal microscopy. Compound #5 had no apparent effect on the nuclear translocation of YAP/TAZ proteins in crypt-like structures ( Figure 5F ).
To further investigate potential mechanisms of action of compound #5, we created a qPCR array of ISC genes and components of major stem cell signaling pathways (Table S1) Figure 6A ), while only the expression level of the hedgehog-driven gene Gli1 (GLI family zinc finger 1) was significantly upregulated ( Figure 6B ).
In order to gain further insight into the mechanism by which compound #5 targets the Hedgehog pathway, we overexpressed Gli. 26 To further confirm engagement of the Hedgehog pathway we 
| DISCUSSION
Nuclear accidents, terrorist attacks with dirty bombs, or deployed nuclear weapons will potentially expose large numbers of the general public and first responders to substantial doses of ionizing radiation. 27 Even in developed countries, the resulting number of victims suffering from ARS will outnumber the capacity of facilities able to provide highend supportive care or bone marrow transplants. 28 Providing care for an overwhelming number of people that would be exposed to radiation in such a scenario would be further complicated by the necessity to deliver treatment as early as possible after exposure. Yet, in a mass-casualty scenario delivering a treatment within the first 24 hours after exposure would be impossible for the majority of the victims. [8] [9] [10] Therefore, current approaches aiming at discovering effective radiation mitigators focus on drugs that show efficacy when given 24 hours (or later) after radiation exposure in order to be of use under such circumstances. 6 Severe damage to the gut will be one of the life-threatening radiation injuries that will require immediate attention. 7 Within hours to days after radiation exposure, the intestinal epithelium responds with massive cell death, villi are lost and the barrier function of the intestines is compromised. Left untreated, victims will succumb to massive loss of fluids, bleeding, malabsorption, and sepsis.
Hypothetically, the intestine's response to radiation could be modified in different ways. A first approach could be through facilitating the repair of DNA damage caused by radiation exposure and prevention of apoptosis. However, in the small intestines, repair of potentially lethal DNA damage after exposure to radiation is a process that starts early after exposure and is mostly completed after 4 hours. 3 Therefore, if a treatment aims at improving or promoting DNA repair any successful intervention would have to be administered in advance or at least rapidly after radiation exposure, which would face the above-mentioned major logistic obstacles if a larger number of people are exposed at the same time. Likewise, apoptosis in the small intestines is a rapid process that peaks at 4 hours after irradiation is completely initiated at 24 hours, 29 thus excluding at least the primary wave of apoptosis as a potential intervention point for radiation mitigators. However, compounds aiming at preventing apoptosis could still be useful in reducing secondary or tertiary waves of programmed cell death in the intestines.
An alternative approach could be the expansion of the ISC pool either from surviving ISCs by stimulation of symmetric divisions, recruitment and interconversion of reserve stem cell populations, or dedifferentiation of differentiating progeny into a stem cell state. [30] [31] [32] Treatments to achieve these goals would allow for a wider time window and would most likely rely on activating pathways involved in ISC and TA cell pool expansion and/or ISC and TA cell interconversion, a process thought to be driven by Wnt, Notch, Hippo, and Hedgehog signaling. 23 Here, we report that treatment with the radiation mitigator compound #5 24 hours after exposure to a lethal dose of radiation led to an increased proliferation of crypt cells 48 hours after irradiation ( Figure 3A-D) , a significant increase in the number of regenerating crypts at 96 hours after irradiation ( Figure 3E ) and a significant increase in survival of the animals (Figure 1 ). The microcolony assay for regenerating crypts used in our study is the gold standard for assessing the number of surviving ISCs 4 and thus, the increase in numbers of regenerating crypts indicated that compound #5 indeed affected the size of the ISC pool ( Figure 1G ). This was further supported by the finding that compound #5 significantly increased the number of budding enteroids in an in vitro intestinal enteroid assay. In these three-dimensional intestinal enteroid (mini-guts) assays the "budding" structures ( Figure 3F ,G) are believed to recapitulate the in vivo crypt structures, which contain the ISC compartment within a niche of other supporting cells. 5 In search for the molecular mechanisms behind our in vitro and in vivo observations we next performed RNASeq. Our results showed that the expression levels of only a surprisingly small number of genes were altered 4 hours after compound #5 treatment ( Figure 4A ). It has to be noted that the whole proximal portion of the duodenum was used for this experiment, which included not only crypts but also the mucosa and submucosa portion of the intestines. This experimental route was chosen to test for global effects of compound #5 on the intestines and because the target cell population was not narrowed down at this point. By design, this experiment did not have the required signal-to-noise ratio that would allow for detection of gene expression changes in only the small population of crypt cells and we interpreted these results as an indicator for a small target cell population for compound #5.
Consequently, we next explored the developmental pathways that govern ISC renewal ( Figure 5 (Figure 7) . Smoothened is known to be expressed in only a small population of pericryptal stromal cells, 33 bone marrow-derived stromal cells 34 and in follicular dendritic cells in the germinal centers. 35 In mouse models of inflammatory bowel disease Hedgehog signaling in stromal cells at the base of the crypt leads to increased IL-10 production as a major anti-inflammatory mechanism. 33 This is in agreement with our observation that compound #5 not only mitigated the GI-ARS but also led to increased cellularity in the germinal centers of Peyer's patches, 21 prevented hematopoietic ARS, 12 increased the number of peripheral CD11b + Ly6C + Ly6G + myeloid cells and stimulated IL-10 production. 12 
